No benefit to bevacizumab in advanced AMD

NEW YORK (Reuters Health) - Intravitreal bevacizumab does not benefit patients with advanced neovascular age-related macular degeneration (AMD) and very poor vision, according to a new 21-patient study.

Full Story →